FDA approves l-amino acid decarboxylase deficiency gene therapy
vol.24 iss.1 (2025) pp.1 Upcoming FDA approval decisions in Q1 2025
vol.24 iss.1 (2025) pp.1 Functional dynamics of G protein-coupled receptors reveal new routes for drug discovery.
(2025) 2024 FDA approvals.
(2025) Engineered T cells traverse new terrain.
(2025) Lipid nanoparticle ferries therapeutic mRNA to the placenta.
(2025) DNA-PKcs inhibitor causes genomic alterations.
(2025) Human brain organoids identify glioma inhibitors.
(2025) Sodium channel blocker reduces skin inflammation.
(2025) Cough suppressant reverses lung scarring.
(2025) Base editing reduces prion protein.
(2025) J&J buys Intra-Cellular Therapies for US$14.6 billion, expanding its neuroscience portfolio.
(2025) 2024 FDA approvals exceed average number but have lower sales projections.
(2025) Biopharma dealmaking in 2024.
(2025) Outlook for medicines development and use in 2025.
(2025) DLL3 draws two antibody-drug conjugate deals.
(2025) FDA approves next-generation triple therapy for cystic fibrosis.
(2025) Targeting inherited mutations to prevent metastasis.
(2025) Designing proteins targeting neosurfaces.
(2025) Degrading aurora kinase A in neuroblastoma.
(2025) The multiple myeloma drug market.
(2025) FDA approves new non-opioid pain drug.
(2025) A new European platform for advancing regulatory science research.
(2025) FDA approves TROP2-targeted antibody-drug conjugate for breast cancer.
(2025) Directing autophagy to degrade cell surface receptors.
(2025) Designer proteins take the bite out of snake venom.
(2025) Peptide blocks phase separation and oncogenic transcription.
(2025) New target to tackle coronaviruses.
(2025) PKC modulator promotes remyelination.
(2025) Approvals by the China NMPA in 2024.
(2025) Clinical development success rates for durable cell and gene therapies.
(2025) Genetics opens new route to degrader discovery.
(2025) Adrenomedullin triggers insulin resistance.
(2025) A platform for personalized ASO therapeutics.
(2025) Reversing lysosomal dysfunction to treat PAH.
(2025) Oral STING agonist inhibits tumour growth.
(2025) Androgen membrane receptor modulates muscle strength.
(2025) Can large, simple trials bring drug developers back to common diseases?
(2025) First muscle-growing antibody heads to the FDA, with obesity opportunities on the horizon.
(2025) Induced proximity pushes beyond protein degraders, as first RIPTAC moves into the clinic
iss.Preprints (2025) ASO targets DNA repair protein to combat Huntington disease.
(2025) GPCR drug discovery: new agents, targets and indications.
(2025) Accelerating adoption of new approach methodologies in regulatory decision making: an industry perspective
iss.Preprints (2025) Wrestling with the RAS cancer drug pipeline.
(2025) Accelerating precision oncology by converging pragmatic trials and real-world evidence
iss.Preprints (2025) A new target for cancer cachexia.
(2025) Fibrosis: cross-organ biology and pathways to development of innovative drugs.
(2025) Computational drug repurposing: approaches, evaluation of in silico resources and case studies.
(2025) Two routes to tamp down microglia in traumatic brain injury.
(2025) Towards an oral norovirus vaccine.
(2025)
vol.24 iss.1 (2025) pp.1 Upcoming FDA approval decisions in Q1 2025
vol.24 iss.1 (2025) pp.1 Functional dynamics of G protein-coupled receptors reveal new routes for drug discovery.
(2025) 2024 FDA approvals.
(2025) Engineered T cells traverse new terrain.
(2025) Lipid nanoparticle ferries therapeutic mRNA to the placenta.
(2025) DNA-PKcs inhibitor causes genomic alterations.
(2025) Human brain organoids identify glioma inhibitors.
(2025) Sodium channel blocker reduces skin inflammation.
(2025) Cough suppressant reverses lung scarring.
(2025) Base editing reduces prion protein.
(2025) J&J buys Intra-Cellular Therapies for US$14.6 billion, expanding its neuroscience portfolio.
(2025) 2024 FDA approvals exceed average number but have lower sales projections.
(2025) Biopharma dealmaking in 2024.
(2025) Outlook for medicines development and use in 2025.
(2025) DLL3 draws two antibody-drug conjugate deals.
(2025) FDA approves next-generation triple therapy for cystic fibrosis.
(2025) Targeting inherited mutations to prevent metastasis.
(2025) Designing proteins targeting neosurfaces.
(2025) Degrading aurora kinase A in neuroblastoma.
(2025) The multiple myeloma drug market.
(2025) FDA approves new non-opioid pain drug.
(2025) A new European platform for advancing regulatory science research.
(2025) FDA approves TROP2-targeted antibody-drug conjugate for breast cancer.
(2025) Directing autophagy to degrade cell surface receptors.
(2025) Designer proteins take the bite out of snake venom.
(2025) Peptide blocks phase separation and oncogenic transcription.
(2025) New target to tackle coronaviruses.
(2025) PKC modulator promotes remyelination.
(2025) Approvals by the China NMPA in 2024.
(2025) Clinical development success rates for durable cell and gene therapies.
(2025) Genetics opens new route to degrader discovery.
(2025) Adrenomedullin triggers insulin resistance.
(2025) A platform for personalized ASO therapeutics.
(2025) Reversing lysosomal dysfunction to treat PAH.
(2025) Oral STING agonist inhibits tumour growth.
(2025) Androgen membrane receptor modulates muscle strength.
(2025) Can large, simple trials bring drug developers back to common diseases?
(2025) First muscle-growing antibody heads to the FDA, with obesity opportunities on the horizon.
(2025) Induced proximity pushes beyond protein degraders, as first RIPTAC moves into the clinic
iss.Preprints (2025) ASO targets DNA repair protein to combat Huntington disease.
(2025) GPCR drug discovery: new agents, targets and indications.
(2025) Accelerating adoption of new approach methodologies in regulatory decision making: an industry perspective
iss.Preprints (2025) Wrestling with the RAS cancer drug pipeline.
(2025) Accelerating precision oncology by converging pragmatic trials and real-world evidence
iss.Preprints (2025) A new target for cancer cachexia.
(2025) Fibrosis: cross-organ biology and pathways to development of innovative drugs.
(2025) Computational drug repurposing: approaches, evaluation of in silico resources and case studies.
(2025) Two routes to tamp down microglia in traumatic brain injury.
(2025) Towards an oral norovirus vaccine.
(2025)
